

NEUROENDOCRINOLOGY

Balancing bodily functions



If you've ever been in the contradictory situation of being simultaneously thirsty and in need of the lavatory, it might be partly due to a microRNA (miRNA). When the body needs water, the hypothalamus increases *Fos* expression, which in turn prevents water secretion by the kidneys. But new work in mice shows that, as *FOS* increases, miR-7b kicks in to suppress further *Fos* expression. Lee and colleagues suggest that, by doing so, miR-7b helps to maintain the body's osmolarity equilibrium. They report their findings in *PNAS*.

The hypothalamus can be considered the master regulator of homeostasis, as it controls body temperature, thirst, hunger, blood pressure and many other autonomic systems to maintain the body's *status quo*. Under conditions of hyperosmolarity (when the body needs to retain water), *Fos* expression in the hypothalamus increases, setting off a chain of events that ultimately reduces water secretion by the

“

...the induction of *FOS* in cultured cells was largely inhibited in the presence of miR-7b ... due to inhibition of translation rather than of mRNA transcription.

”

kidneys. Water secretion cannot be allowed to stop entirely, however, and following the increase, *FOS* levels reach a steady state if the hyperosmolarity still persists or rapidly drop down as the condition improves. This occurs by protein degradation and, as Lee *et al.* now show, by inhibiting *Fos* expression.

miRNAs inhibit protein expression by binding to target mRNAs and either degrading them or preventing their translation. The team identified miR-7b during a search for hypothalamic miRNAs

CIRCADIAN RHYTHMS

Feeding time

When food is scarce, being able to anticipate the time when it is available has great survival benefits. The timing of food-seeking behaviour is thought to be driven by circadian body clocks that can be reset by nutritional cues, but how these food-entrainable oscillators work at the molecular level is unknown. The two period genes, *Per1* and *Per2*, are known to be crucial for light-induced resetting of the main body clock, which is housed in the hypothalamic suprachiasmatic nucleus (SCN). Reporting in *Current Biology*, Feillet and colleagues investigated the role of these genes in food anticipation.

Nocturnal animals, which are normally most active at night, will shift their activity pattern if their only meal occurs in daytime. Indeed, wild-type mice exposed to restricted feeding times or to hypocaloric food show bouts of locomotor activity just before mealtimes. The researchers found that

while mice lacking *Per1* displayed similar food-anticipatory behaviour, *Per2* mutants were unable to predict the time of food access. When tested in constant light or constant dark conditions, *Per2* mutants still could not anticipate food availability, indicating that this inability was independent of light cues and that *Per2* is crucial for the capacity to anticipate the timing of meals.


Next, the researchers set out to test whether *Per1* and *Per2* have a role in the food-induced resetting of the SCN. This central oscillator regulates the free-running rhythms of, amongst others, locomotor activity and temperature that become apparent when animals are housed in constant darkness. In wild-type mice, food restriction causes a phase advance in these rhythms. However, the free-running rhythm of *Per1* mutants' locomotor activity displayed a phase delay, whereas that of *Per2* mutants showed a large phase advance.

“

...*Per1* and *Per2* are involved in the mechanism by which nutritional cues entrain the central, but not peripheral clocks...

”

At the molecular level, the expression of clock genes *Bmal1* and *Cry1* in the SCN in response to limited food availability was also different in *Per1* and *Per2* mutants compared with wild-type



that were increased or suppressed by prolonged hyperosmolarity (saline ingestion) in mice. miR-7b, which showed increased expression, was found to have potential binding sites in the 3' untranslated region of *Fos* mRNA. The team confirmed that *Fos* was indeed a target of miR-7b, showing that the induction of FOS in cultured cells was largely inhibited in the presence of miR-7b and that this was due to inhibition of translation rather than of mRNA transcription.

The team identified a number of hypothalamic miRNAs that are both up- and downregulated in the body's reaction to hyperosmolarity. It will therefore be interesting to determine whether these could also be involved in the fine-tuning of osmolarity control by the hypothalamus and what their potential targets might be.

Ruth Williams

ORIGINAL RESEARCH PAPER Lee, H.-J. *et al.* miR-7b, a microRNA up-regulated in the hypothalamus after chronic hyperosmolar stimulation, inhibits Fos translation. *Proc. Natl Acad. Sci. USA* **103**, 15669–15674 (2006)

mice. Furthermore, in *Per2* mutants, expression of the clock-controlled genes *Dbp* and *Avp* in the SCN was greatly reduced.

Although these results indicated that *Per1* and *Per2* have a role in the resetting of the central body clock by nutritional cues, peripheral food-entrainable oscillators did not require *Per1* and *Per2*. Using quantitative PCR, the researchers showed that food restriction caused phase shifts in the expression of clock genes *Bmal1* and *Rev-Erb α* and the clock-controlled gene *Dbp* in the liver and kidney that were similar in *Per1* and *Per2* mutants and in wild-type mice.

This study provides evidence that that *Per1* and *Per2* are involved in the mechanism by which nutritional cues entrain the central, but not peripheral clocks and shows for the first time that *Per2* is crucial for the ability to anticipate circadian cycles of food availability.

Leonie Welberg

ORIGINAL RESEARCH PAPER Feillet, C. A. *et al.* Lack of food anticipation in *Per2* mutant mice. *Curr. Biol.* **16**, 2016–2022 (2006)



CANCER

Rooting out resistance

Glioblastomas are aggressive brain tumours that rapidly become resistant to radiotherapy. Jeremy Rich and colleagues now show that glioma stem cells are the root of this problem.

Glioblastomas present as diffuse tumours that invade normal brain tissue, and patients who are diagnosed with this disease have a median survival of less than 12 months. Glioblastomas recur after treatment with radiation, but often as focal masses, suggesting that only a small proportion of cells are responsible for recurrence. Both normal brain stem cells and brain tumour stem cells have recently been characterized, and cells that express prominin 1 (also known as CD133) often show stem-cell-like characteristics.

Rich and colleagues asked whether the glioma subpopulation of CD133⁺ cells is involved in the development of radioresistance. A fourfold enrichment of the CD133⁺ cell population from human explants is evident after treatment with ionizing radiation *in vitro*, and the authors showed that radiation does not induce CD133 expression in CD133⁻ cells. In addition, increasing the percentage of CD133⁺ cells in a defined number of glioblastoma tumour cells decreases the time taken for the tumours to grow in the frontal lobes of immuno-compromised mice, indicating the enrichment of tumorigenic stem cells.

So, are CD133⁺ glioma stem cells more resistant to radiotherapy? *In vitro* colony-formation assays after the irradiation of either CD133⁻ or CD133⁺ cells from the same patient or xenograft confirmed that more CD133⁺ cells survive this treatment. Moreover, viable CD133⁺ cells from irradiated xenografts formed

secondary tumours in mice with the same kinetics as CD133⁺ cells that had not been irradiated, indicating that 2 Gy of radiation does not reduce the tumour-forming capacity of these cells.

Why can these cells survive radiation treatment? The authors analysed DNA-damage checkpoints in both the CD133⁻ and CD133⁺ cell populations, and found that CD133⁺ cells show greater activation (levels of phosphorylation) of DNA-damage checkpoint proteins such as ataxia telangiectasia mutated (ATM) and RAD17. Although both cell populations sustain the same level of DNA damage (shown by analysing DNA



Drugs that target the DNA-damage checkpoint are in pre-clinical and clinical trials ... their use might improve the outcome for patients...



double-strand breaks using the comet assay) in response to irradiation, the repair of these breaks occurs 4–9 times more rapidly in CD133⁺ cells. The pre-treatment of CD133⁺ cells with an inhibitor of the DNA-damage checkpoint kinases CHK1 and CHK2 reduced the survival of these cells after irradiation *in vitro*.

Drugs that target the DNA-damage checkpoint are in pre-clinical and clinical trials, and these results suggest that their use might improve the outcome for patients with glioblastoma and potentially other solid tumours.

Nicola McCarthy, Senior Editor,
Nature Reviews Cancer

ORIGINAL RESEARCH PAPER Bao, S. *et al.* Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* **18** October 2006 (doi:10.1038/nature05236)